These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1305425)

  • 41. [Relation between the structure and action on cholinergic structures of alpha, omega-bis(trimethylammoniomethyl)oligodimethyl-siloxanes].
    Danilov AF; Lukomskaia NIa; Pershina LI; Magazanik LG; Potap'eva NN
    Dokl Akad Nauk SSSR; 1982; 265(1):228-32. PubMed ID: 6213395
    [No Abstract]   [Full Text] [Related]  

  • 42. [The influence of aminostigmine on the parameters of nonspecific resistance and immune system of the organism upon acute poisoning of benzyl 3-quinuclidylate].
    Zabrodskiĭ PF; Troshkin NM; Germanchuk VG; Sidel'nikova NM; Lim VG
    Eksp Klin Farmakol; 2005; 68(6):40-2. PubMed ID: 16405033
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of pyridostigmine and syntostigmine pretreatment on the inhibition of acetylcholinesterases by o-pinacolyl-methylphosphonofluoridate. In vitro experiments with rat tissues.
    Patocka J
    Biomed Biochim Acta; 1989; 48(9):715-20. PubMed ID: 2619740
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [On the pharmacology of sanguinarine, an anticholinesterase alkaloid].
    Nikol'skaia BS
    Farmakol Toksikol; 1966; 29(1):76-9. PubMed ID: 6011209
    [No Abstract]   [Full Text] [Related]  

  • 45. Ketamine antagonizes toxic action of anticholinesterase agents.
    Contreras CM; Marvan ML; Mexicano G; Puente A; Morfin A
    Bol Estud Med Biol; 1990; 38(1-2):10-5. PubMed ID: 2291776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Possibility of usage of aminostigmine structural analogue for the treatment of toxic cognitive disorders.
    Fateev IV; Subbotina SN; Kurpyakova AF; Tyunin MA
    Bull Exp Biol Med; 2014 Jan; 156(3):353-6. PubMed ID: 24771374
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Some pharmacological correlations of hypothermia induced by anticholinesterasics.
    Voicu V; Jiquidi M; Sitcal N; Bruja N
    Physiologie; 1976; 13(4):285-91. PubMed ID: 828747
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effects of tri-aryl phosphates upon cholinesterase.
    Bondy HF; Hughes JP; Leahy JS; Worden AN
    Toxicology; 1973 Jun; 1(2):143-50. PubMed ID: 4795109
    [No Abstract]   [Full Text] [Related]  

  • 49. Effect of oximes on the acute toxicity of anticholinesterase carbamates.
    Natoff IL; Reiff B
    Toxicol Appl Pharmacol; 1973 Aug; 25(4):569-75. PubMed ID: 4741778
    [No Abstract]   [Full Text] [Related]  

  • 50. [Possible anticholinesterase activity of the tetanus toxin].
    Leonardi G
    Ann Sclavo; 1971; 13(2):153-228. PubMed ID: 4340980
    [No Abstract]   [Full Text] [Related]  

  • 51. The esterases of cavian plasma.
    Chow AY; Ecobichon DJ
    Rev Can Biol; 1972 Mar; 31(1):21-9. PubMed ID: 4111735
    [No Abstract]   [Full Text] [Related]  

  • 52. Red cell and plasma cholinesterase activities in microsamples of human and animal blood determined simultaneously by a modified acetylthiocholine-DTNB procedure.
    Voss G; Sachsse K
    Toxicol Appl Pharmacol; 1970 May; 16(3):764-72. PubMed ID: 5422218
    [No Abstract]   [Full Text] [Related]  

  • 53. Subchronic administration of various pretreatments of nerve agent poisoning. I. Protection of blood and central cholinesterases, innocuousness towards blood-brain barrier permeability.
    Lallement G; Foquin A; Dorandeu F; Baubichon D; Aubriot S; Carpentier P
    Drug Chem Toxicol; 2001 May; 24(2):151-64. PubMed ID: 11360432
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anticholinesterase agents affect contrast gain of the cat cortical visual evoked potential.
    DeBruyn EJ; Gajewski YA; Bonds AB
    Neurosci Lett; 1986 Nov; 71(3):311-6. PubMed ID: 3796887
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation between animal and clinical findings with a psychotomimetic anticholinesterase.
    Wray SR; Cowan A
    Neuropharmacology; 1973 Apr; 12(4):397-400. PubMed ID: 4703881
    [No Abstract]   [Full Text] [Related]  

  • 56. INFLUENCE OF SKF525-A ON THE BEHAVIORAL AND ANTICHOLINESTERASE EFFECTS OF CERTAIN CARBAMATES.
    GOLDBERG ME; JOHNSON HE; KNAAK JB
    Biochem Pharmacol; 1964 Nov; 13():1483-8. PubMed ID: 14239623
    [No Abstract]   [Full Text] [Related]  

  • 57. POTENTIATION OF CHLORPROMAZINE-INDUCED BEHAVIOURAL CHANGES BY ANTICHOLINESTERASE AGENTS.
    GOLDBERG ME; JOHNSON HE
    J Pharm Pharmacol; 1964 Jan; 16():60-1. PubMed ID: 14106567
    [No Abstract]   [Full Text] [Related]  

  • 58. The anticholinesterase activity of physostigmine.
    Hemsworth BA; West GB
    J Pharm Pharmacol; 1968 May; 20(5):406-7. PubMed ID: 4385453
    [No Abstract]   [Full Text] [Related]  

  • 59. [CHARACTERIZATION OF THE CHOLINESTERASE ACTIVITY IN VITRO OF SOME BIOLOGICAL MATERIALS OF VARIOUS ORIGINS BY SELECTIVE INHIBITORS OF TRUE CHOLINESTERASE].
    GESSA GL; VARGIU L; FERRARI W
    Boll Soc Ital Biol Sper; 1963 Sep; 39():986-8. PubMed ID: 14091358
    [No Abstract]   [Full Text] [Related]  

  • 60. Interactions between anticholinesterase agents and neuroleptics in terms of cholinesterase inhibition in brain and other tissues of rats.
    Michalek H; Nemesio R; Meneguz A; Bisso GM
    Arch Toxicol Suppl; 1983; 6():386-90. PubMed ID: 6138014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.